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Two types of receptors for the Fc portion of human IgE (FccR) have been
identified on the surface of human cells . These two types of receptors differ in
their affinity for IgE as well as in their cellular distribution and function (1) .
Type 1 FcER (FcERI) show high affinity (109/M) for IgE and are detectable on
mast cells and basophils (2) . The reaction between allergens and IgE bound to
FCERI induces degranulation of basophils and mast cells, with release of chem-
ical mediators responsible for the clinical manifestations of allergy (3) . In con-
trast, type 2 FCER (FcER2) bind IgE with a lower affinity (10'-10"/M) and are
present on monocytes, macrophages, B lymphocytes, platelets, and eosinophils
(4) . The binding of IgE to FcER2 on monocytes, eosinophils, and platelets acti-
vates a variety of effector functions in these cells (3, 5, 6) .
It is well known that the frequency of human peripheral blood monocytes
(Mo)' bearing FcER2 is increased in atopic subjects, particularly in the presence
of high serum IgE levels, while it is negligible in normal subjects (3) . In addition,
it has been recently reported that Mo bearing cytophilic IgE infiltrate into the
skin lesions of patients with atopic dermatitis (7) . The role of FcER2+ Mo in the
pathogenesis of allergic disorders is, however, still poorly understood . Binding
of IgE to FcER2 sensitizes rodent peritoneal (8) and alveolar (9) macrophages to
the release of leukotrienes and arachidonic acid upon exposure to allergen .
The signals that are able to induce the expression of FcER2 on Mo, however,
have not been defined . In the present study, we have examined the ability of a
variety of recombinant lymphokines and monokines to induce on human normal
peripheral blood Mo the expression of FcER2, as detected by IgE binding . In
parallel, we have investigated the ability of the same agents to induce the expres-
sion on Mo of the CD23 antigen, as detected by mAb binding . CD23 has been
described as a B cell-specific activation antigen (10) and more recently has been
shown to be identical to the B cell FcER2 (11, 12) and to the Blast-2 antigen
expressed by B cells upon activation by a variety of stimuli (13, 14) . Our data
indicate that the expression of FcER2/CD23 by normal human Mo can be spe-
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cifically induced by IL-4/B cell stimulatory factor 1 (BSF-1), but not by IL-1,
IL-2, IL-3, IL-5, BSF-2, granulocyte/macrophage colony-stimulating factor
(GM-CSF), and IFN-7.
Materials and Methods
Immunoglobulin and Antibodies.
￿
Human myeloma IgE (PS) (a kind gift of Dr. K. Ishi-
zaka, Johns Hopkins University, Baltimore, MD) was purified as previously described
(15). A FITC-conjugated, affinity-purified goat anti-human IgE(PS) (GAHE) was pre-
pared as previously described (16). The murine mAb 25 raised against the human B cell
line RPMI 8866 and specific for CD23/FceR2 (11) was kindly provided by Drs. J. Banch-
ereau and J. de Vries, UNICET Laboratory for Immunological Research, Dardilly,
France. The mouse anti-human anti-Blast-2 (EBVCS2) mAb (13) was a kind gift of Dr.
B. Sugden, McArdle Laboratory for Cancer Research, Madison, WI. Anti-HLA-Dr, anti-
Leu-M3 (unconjugated and phycoerythrin (PE)-conjugated) and anti-Leu-16 mAbs,
FITC-conjugated goat anti-mouse IgG (GAMIG), and control mAbs of appropriate Ig
isotypes were purchased from Becton Dickinson Monoclonal Center (Mountain View,
CA). Plt-1, a murine IgM mAb specific for the glycoprotein IIb-111a on human platelets,
was purchased from Coulter Immunology (Hialeah, FL). A FITC-conjugated goat anti-
mouse IgM was obtained from Tago Inc. (Burlingame, CA).
Interleukins.
￿
Human rIL-4 was kindly provided by Dr. K. Arai, DNAX Research Insti-
tute of Cellular and Molecular Biology (Palo Alto, CA) as supernatants from COS-7 cells
transfected with the pcD vector containing the human IL-4 cDNA clone. Mock super-
natants from COS-7 cells transfected with an unrelated cDNA clone (mock sup) were
used as a negative control. Human rIL-1 (3, rIL-2, rIL-3, and rIFN-'y were obtained from
Cistron (Pine Brook, NJ), Amgen Biologicals (Thousand Oaks, CA), Genzyme Corpora-
tion (Boston, MA), and Biogen Corporation (Cambridge, MA), respectively. Human
rGM-CSF and rIL-5 were a kind gift of Dr. S. Clark, Genetics Institute (Cambridge, MA).
Human rBSF-2 was a kind gift of Dr. T. Kishimoto, Institute for Cellular and Molecular
Biology, Osaka, Japan.
Isolation ofPeripheral Blood Mo.
￿
PBMCs were isolated from heparinized venous blood
of healthy human donors by Ficoll-Hypaque density gradient centrifugation. The cells
were then resuspended in RPMI 1640 (M.A. Bioproducts, Walkersville, MD) supple-
mented with 10% AB' serum (Hazleton Research Products, Lenexa, KA), 2 mM gluta-
mine, 50 jug/ml streptomycin, and 100 U/ml penicillin (complete medium), and were
adhered overnight at 37°C in a 5% C02 atmosphere in plastic petri dishes. After remov-
ing the nonadherent cells, the dishes were extensively washed with warm medium and
then incubated with cold PBS on ice for 15 min. The adherent Mo were subsequently
recovered by vigorous pipetting, washed, and resuspended in complete medium at 106
cells/ml. The Mo preparations contained >95% Leu-M3 + cells and <3% Leu-16+ cells,
as detected by immunofluorescence staining. Platelet contamination (10-20%), as
assessed by staining with the Plt-1 murine mAb, was detectable in some Mo preparations.
Cell viability, as determined by trypan blue exclusion, was always >95%.
Cell Cultures.
￿
After preliminary experiments to establish the optimal concentration
of each IL, purified Mo (106 cells/ml) were incubated with rIL-4 (50 U/ml), rGM-CSF
(1 ng/ml), rIFN-7 (200 U/ml), rIL-1 (10 U/ml) rIL-2 (10 U/ml), rIL-3 (50 U/ml), rIL-
5 (50 U/ml), rBSF-2 (100 U/ml), and mock supernatants. After 24-48 h, the cells were
washed and analyzed by immunofluorescence to assess the expression of FceR2/CD23 .
In some experiments, purified Mo (106 cells/ml) were incubated with various concen-
trations (0.1-100 ng/ml) of PMA (Sigma Chemical Co., St. Louis, MO) with, or without,
10uM ionomycin (Calbiochem-Behring Corp., La Jolla, CA).
In control experiments, human platelets (1 .5 X 108/ml) purified from three different
normal donors as previously described (6) were incubated with rIL-4 (50 U/ml) for 24 h
and subsequently analyzed by flow cytometry for FceR2/CD23 expression.
Immunofuorescence (IF) Staining for FceR2/CD23.
￿
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Mo incubated with different ILs was evaluated by indirect IF. (a) 0.5 X 106 Mo in stain-
ing buffer (RPMI 1640/2.5% FCS, containing 0.01% sodium azide) were incubated with
IgE (PS) (10 wg/ml) for 40 min at 4°C. After washing, the cells were incubated for 30
min at 4°C with GAHE-FITC and finally extensively washed. (b) In parallel, Mo were
incubated for 40 min at 4°C with appropriate dilutions of mAb 25 or anti-Blast-2 mAb
and, after washing, with GAMIG-FITC for 30 min at 4°C. As a control, an unrelated
mouse IgG mAb was used, followed by GAMIG-FITC, under the same conditions. The
percentage of Mo binding IgE and the CD23-specific mAbs was evaluatedby a FAGS cell
analyzer (Becton Dickinson & Co.) . Background staining (always <5%) was subtracted
from the experimental values. To evaluate the expression of HLA-Dr antigens, purified
Mo were stained with anti-HLA-Dr mAb followed by GAMIG-FITC, and median channel
fluorescence (MCF) was determined. MCF, a measure of fluorescence intensity, corre-
lates well with antigen density (17). MCF of the control was subtracted from the MCF of
each sample.
For binding inhibition assays, 0.5 X 106 FceR2/CD23+ U937 cells were preincubated
with medium, anti-Blast-2 mAb (1 ug/ml), or a control IgGI murine mAb (anti-HLA-DP,
2.5 tig/ml) for 60 min at 4°C. The cells were then washed twice and incubated for 40
min at 4°C with mAb 25-FITC (1 teg/ml) or with IgE(PS) (1 wg/ml) followed by GAHE-
FITC. After extensive washing, the percentage of cells binding the second ligand was
assessed as described above. The background value was determined by the percentage of
cells stained by a FITC-conjugated control mAb of IgGI isotype or by GAHE-FITC.
For two-color IF staining, purified Mo (0.5 X 106 cells/ml) in staining buffer were
incubated with appropriate dilutions of mAb 25-FITC and anti-Leu-M3-PE for 40 min
at 4°C. After extensive washing, the percentage of double-staining cells was evaluated by
FACS analysis. Unrelated fluorochrome-conjugated murine mAbs of the appropriate IgG
isotype were used as controls. Background staining was subtracted from the experimental
values.
Surface Iodination and Immunoprecipitation.
￿
Purified Mo (20 X 106 cells) were incu-
bated with medium or rIL-4 (50 U/ml) for 48 h. The cells were then washed, suspended
in 0.2 ml of PBS, and surface iodinated (1 MCi 1251-Na; New England Nuclear, Boston,
MA) by the lactoperoxidase method (18) . FceR2/CD23+ U937 and RPMI 8866 cellswere
treated under the same conditions. The cell membranes were solubilized at 4°C in 0.3
ml of lysis buffer containing 1.5% NP-40 in PBS and proteolytic enzyme inhibitors: 1
mM PMSF (Sigma Chemical Co.), 1mM EDTA, 10 mM iodoacetamide, and 1 Ag/ml of
leupeptin, antipain, chymostatin, and pepstatin (Sigma Chemical Co.). Cell lysates were
clarified by centrifuging at 100,000 g for 20 min at 4°C and were incubated overnight
with 10 A1 of a 10% suspension of Staphylococcus aureus organisms (IgGsorb, The Enzyme
Centre Inc., Malden, MA). This was followed by three absorption cycles, each consisting
of a 2-h incubation with 30 A1 of protein A-Sepharose 4B beads (Pharmacia Fine Chem-
icals, Piscataway, NJ) coupled to normal mouse IgG (CooperBiomedical, Inc., Malvern,
PA). Immunoprecipitation was then performed by incubating the clarified cell lysates
with mAb 25 (10 wg) bound to protein A-Sepharose 4B (20 A.1). As a negative control,
the cell lysates were immunoprecipitated with 10 ug of normal mouse IgG coupled to
protein A-Sepharose 4B. In some experiments, immunoprecipitation was performed
with IgE(PS) coupled to Sepharose 4B (10 mg/ml). The beads were extensively washed
wtih lysis buffer and then eluted by boiling for 5 min in electrophoresis sample buffer.
The samples were analyzed by SDS-PAGE according to the method of Laemmli (19),
and autoradiographed (Kodak diagnostic film XAR-5).
Results
rIL-4 Induces the Expression ofFccR21CD23 on Normal Human Mo.
￿
To identify
soluble signals able to induce and/or upregulate the expression of FceR2 on
normal human Mo, purified Mo were incubated with a variety of rILs. 24-48 h
later, the Mo were assayed by flow cytometry for the expression of FcER2 usingVERCELLI ET AL.
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FIGURE 1 .
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Human rIL-4 induces the expression of FceR2/CD23 on normal human Mo .
Purified human Mo were incubated for 24-48 h with rIL--4 (50 U/ml), rIL-1 (10 U/ml), rIL-
2 (10 U/ml), rIL-3 (50 U/ml), rIL-5 (50 U/ml), rBSF-2 (100 U/ml), rIFN- -Y (200 U/ml), rGM-
CSF (1 ng/ml), and mock sups. The Mo were then assayed by flow cytometry for the expres-
sion of FceR2 (using soluble IgE followed by GAHE-FITC [a]) and CD23 (using mAb 25
followed by GAMIG-FITC [b]) . The data represent the mean ± SE of 11 experiments . Sta-
tistical analysis was performed by a two-tailed Student's t test. (**) p < 0.001 .
soluble IgE and a FITC-conjugated affinity-purified GAHE . The results of 11
experiments are shown in Fig. 1 a. The baseline expression ofFceR2 on normal
Mo was negligible (<6%). Incubation with rIL-4 (50 U/ml), however, induced
a significant (]b < 0.001) increase in the expression of FceR2 . Induction of RE
R2 by rIL-4 was specific, since a mock COS-7 transfection supernatant had no
effect on FceR2 expression (data not shown) . In contrast, no significant increase
in FceR2 was observed when Mo were incubated with rIL-1 (10 U/ml), rIL-2 (10
U/ml), rIL-3 (50 U/ml), rIL-5 (50 U/ml), rBSF-2 (100 U/ml), rIFN--y (200 U/
ml), rGM-CSF (1 ng/ml), either alone (Fig. 1 a) or in various combinations (data1410
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FIGURE 2. Flow cytometry analysis of rIL-4-induced FceR2/CD23
expression on normal human Mo. Purified human Mo incubated for
24 h with medium (- - -) or Y11,4 (50 U/ml) (-) were assessed by
IF for the expression of FceR2/CD23, as detected by the CD23-spe-
ci6c mAb 25 followed by GAMIG-FITC. The shaded area represents
the FceR2/CD23 + cell population.
not shown) . No synergism was observed between IL-4 and other ILs (data not
shown) . Fig. 2 shows a representative example of the level of rIL-4-induced
FceR2 expression observed by flow cytometry.
In Fig. I b, Mo were incubated with the same combinations of ILs. In these
experiments, however, the expression of CD23 was assessed by IF using mAb
25, which recognizes CD23/FceR2 on RPMI 8866 B cells (11). A comparison of
Fig. 1 a and 1 b clearly indicates that the expression of FceR2 (as assessed by
soluble IgE binding) and CD23 (as assessed by anti-CD23 mAb binding) fol-
lowed an identical pattern.
The same pattern was also obtained when the induction of the Blast-2 antigen
(as detected by anti-Blast-2 mAb binding) was studied (data not shown). The
Blast-2 antigen has to date been considered a B cell-specific activation marker
expressed by B cells upon stimulation with EBV or mitogens (13, 14). To further
investigate the relationship between FceR2/CD23 and Blast-2 on Mo, we exam-
ined the ability of the anti-Blast-2 mAb to inhibit the binding of IgE and/or
mAb 25 to the human promonocytic cell line U937. U937 cells constitutively
express FceR2/CD23 and Blast-2 at high levels (82 ± 1 and 88 ± 1%, respec-
tively, as assessed by IF). As shown in Table I, anti-Blast-2 mAb strongly inhib-
TABLE I
Anti-Blast-2 mAb Inhibits the Binding ofmAb25 and IgE to U937 Cells
0.5 X 10s U937 cells in staining buffer were preincubated with medium, anti-Blast-2
mAb (I ug/ml), or a control IgG1 murine mAb (anti-HLA-DP, 2.5 ,g/ml) for 60 min
at 4°C. After washing, the cellswere then incubated for 40 min at 4°C with mAb 25-
FITC (I jg/ml) or with IgE(PS) (I jAg/ml) followed by GAHE-FITC. The table shows
the percentage of positive cells subtracted for the background (percentage of cells
stained by a FITC-conjugated control mAb of IgGI isotype or by GAHE-FITC). The
data representthe mean ± SE of three experiments.
Preincubation with: Second ligand Positive cells Inhibition
Medium mAb 25-FITC 75 ± 3 -
Anti-Blast-2 mAb 25-FITC 6 ± 1 92
Control mouse
IgGI mAb 25-FITC 68 ± 2 10
Medium IgE+GAHE-FITC 84 ± I -
Anti-Blast-2 IgE+GAHE-FITC 20 ± 2 71
Control mouse
IgGI IgE+GAHE-FITC 70 ± 3 17m
NN 0
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u
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ited the binding of mAb 25 (92% inhibition) and IgE (77% inhibition) to U937
cells. No significant inhibition was detectable using a control IgG1 mAb. These
data indicate that the FcER2/CD23 and Blast-2 antigens expressed by human Mo
are closely related, if not identical.
We next wished to confirm that the IL-4-induced FcER2/CD23 was expressed
on Mo, and not on contaminating B cells and/or platelets. To this purpose, pur-
ified Mo incubated with rIL-4 were analyzed by two-color IF for simultaneous
reactivity with mAb 25-FITC and anti-Leu-M3-PE. In four experiments, the per-
centage of cells stained with both the anti-Leu-M3 and mAb 25 antibodies rose
from 4 ± 1% in control cultures to 49 ± 3% in the rIL-4-treated cultures.
Furthermore, rIL-4 had no effect on FcER2/CD23 expression (as assessed by
flow cytometry using soluble IgE or CD23-specific mAbs) by purified human
platelets from three different donors (data not shown). These data indicate that
Mo indeed express FcER2/CD23 upon stimulation with rIL-4.
Kinetics of the IL-4-induced Expression of FceR2/CD23 on Mo.
￿
The time course
of FcER2/CD23 expression was assessed by flow cytometry at various times after
the addition of human rIL-4 (50 U/ml). As shown in Fig. 3, FcER2/CD23 was
still absent after 8 h of incubation with rIL-4, peaked 24 h after the addition of
rIL-4, and was still clearly detectable after 72 h of incubation with rIL-4. The
same kinetics pattern was obtained monitoring the induction of the Blast-2 epi-
tope (data not shown) .
Immunoprecipitation of FceR2/CD23 from Human Mo.
￿
To confirm the induc-
tion of the CD23 antigen on normal human Mo upon stimulation with rIL-4,
normal human Mo (preincubated for 48 h with medium or rIL-4 [50 U/ml])
were surface labeled with
125I, then lysed and immunoprecipitated with mAb 25 .
As shown in Fig. 4, incubation with rIL-4 (Fig. 4, lane 3) induced the appear-
Tlrne (h)
-w FceR2+ MO
-40- CD23+ MO
FIGURE 3.
￿
Kinetics of the expression of FceR2/CD23 induced by rIL-4 on Mo. Purified
human Mo were incubated with rIL-4 (50 U/ml) and assessed by flow cytometry at various
times for the expression of FceR2 (using soluble IgE followed by GAHE-FITC) and CD23
(using mAb 25 followed by GAMIG-FITC). The data represent the mean ± SE of three
experiments.141 2
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FIGURE 4 .
￿
SDS-PAGE analysis of FceR2/CD23 immunoprecipi-
tated from normal human Mo (preincubated with medium or rIL-
4), U937 cells, and RPMI 8866 cells . The cells were surface
labeled with 1251 and lactoperoxidase and then lysed . The cell
lysateswere then immunoprecipitated with the CD23-specific mAb
25 antibody and analyzed by 1240 SDS-PAGE under nonreducing
conditions . (Lane 1) Molecular weight markers. (Lane 2) Normal
Mo preincubated with medium, (lane 3) normal Mo preincubated
with rIL-4 (50 U/ml) for 48 h, (lane 4) U937 cells, (lane 5) RPMI
8866 cells .
ance of a radiolabeled band with an apparent size of 45 kD . This band was
almost undetectable on unstimulated Mo (Fig . 4, lane 2) and completely absent
in control lanes (data not shown) . The 45-kD protein had the same migration
pattern under both nonreducing and reducing conditions (data not shown) . A
45-kD band could also be precipitated from U937 cells (Fig . 4, lane 4), which
constitutively express high amounts of FceR2/CD23 . The bands specifically pre-
cipitated by mAb 25 from the lysates of IL-4-induced Mo and U937 cells were
identical to the FceR2/CD23 band precipitated by mAb 25 from RPMI 8866 B
cells (Fig . 4, lane 5) . The 45-kD protein could be precipitated by IgE as well as
by mAb 25 (data not shown) . These data further confirm that FceR2/CD23 can
be induced on normal Mo by rIL-4 and that the low-affinity FCER on Mo and B
cells share the CD23 epitope recognized by mAb 25 .
rIFN-y Does not Inhibit IL-4-induced FccR21CD23 Expression on Normal Mo .
￿
It
has recently been reported that the IL-4-dependent induction of FcER2/CD23
on normal human B cells can be inhibited by rIFN-y (20, 21) . We investigated
the effect of rIFN-y (200 U/ml) on the expression of FcER2/CD23 induced on
TABLE II
Effects of rIFN-y on IL-4-induced FceR2/CD23 and HLA-Dr
Expression by Normal Human Mo
Purified humanMo were incubated with rIL-4 (50 U/ml), rIFN-y (200 U/
ml), or rIFN-y + r-IL4 . 48 h later,Mo were assessed by IF for the expres-
sion of FceR2/CD23 and HLA-Dr antigens, as described in Material and
Methods . The table shows the mean ± SE of the results obtained in six
experiments .
IL FceR2+/CD23+ HLA-Dr' (MCF)
Nil 7.7±2.5/6.2±2 .3 120±7
AL-4 25.7±4.4/31.0±9.4 129±9
rIFN-y 7 .8 ± 2.5/8.8 ± 3.2 151 ± 2
rIFN--y + rIL-4 23 .6 ± 5.2/28.6 ± 9.4 140 ± 9VERCELLI ET AL.
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human Mo by rIL-4 (50 U/ml). Although rIFN-y markedly increased HLA-Dr
expression on Mo, it could not inhibit the expression of FceR2/CD23 when
added to the Mo culture together with rIL-4 (Table II) . No effect was observed
even when rIFN-y was added to the culture 36 h before rIL-4 (data not shown) .
Discussion
The results of this study show that rIL-4 specifically induces the expression
of the low-affinity receptor for the Fc portion of IgE (FceR2) on normal human
Mo. FceR2/CD23 induction could be detected both by flow cytometry (using
anti-CD23 mAbs and soluble IgE in one- and two-color IF) and by immunopre-
cipitation with CD23-specific mAb or IgE coupled to Sepharose. FceR2/CD23
on Mo is closely related, if not identical, to the Blast-2 antigen, which has to
date been considered as a marker restricted to activated B cells (13, 14) . FceR2/
CD23/Blast-2 is therefore expressed on cells belonging to different lineages.
FceR2/CD23 was fully expressed after a 24-h incubation with rIL-4, and was
still detectable 72 h after the addition of IL-4. None of the other rILs tested
(IL-1, IL-2, IL-3, IL-5, BSF-2, GM-CSF, and IFN-y) could induce FceR2/CD23,
either alone or in various combinations. No synergism was observed between IL-
4 and other ILs. Under these experimental conditions, human IgE did not sig-
nificantly increase IL-4-induced CD23 expression on Mo, as assessed by staining
with CD23-specific mAbs (Vercelli, D., and D. Y. M. Leung, unpublished obser-
vations) . PMA ± ionomycin (data not shown) and IFN-y, powerful Mo activa-
tors able to significantly increase HLA-Dr expression, could not induce FceR2/
CD23 . Such findings suggest that different kinds of stimuli can induce different
states of Mo activation. This is consistent with the recent observation that IFN-
y and bacterial surface molecules (such as LPS and muramyl dipeptide) induce
different patterns of mRNA expression in Mo (22).
Interestingly enough, the expression of FceR2/CD23 on Mo and B cells seems
to be regulated differently; IFN-y was not able to inhibit the IL-4-induced
expression of FceR2/CD23 on Mo, neither when added to the culture together
with IL-4, nor when added 36 h earlier. In contrast, it has been recently
reported that IFN-y has a strong inhibitory effect on the IL-4-dependent induc-
tion of FceR2/CD23 on human B cells (20). In addition, phorbol esters could
not increase FceR2/CD23 expression on Mo, while an inducing effect has been
recently described for B cells (23, 24). Recent evidence suggests that FceR2/
CD23 may play a crucial role in growth signal transduction on the B cell surface
(23-26). The biological significance of FceR2/CD23 on Mo remains to be
established.
Previous reports have mainly focused on the various effects of IL-4 on B and
T cells (reviewed in Reference 27) . However, it has been recently reported that
IL-4 is able to activate mouse macrophages, increase their tumoricidal activity
and Ia antigens expression (28), and enhance their antigen-presenting capacity
(29). The activity of IL-4 on macrophages is consistent with the detection of IL-
4-specific high-affinity receptors on murine macrophage lines (30) and thiogly-
colate-stimulated peritoneal macrophages (31), as well as on the human pro-
monocytic U937 cell line (32) . The present study is the first report of an IL-4
effect on normal human Mo. Our results further confirm that IL-4 is a multi-141 4
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functional lymphokine, able to act on cells belonging to different lineages.
The observation that IL-4 can strongly induce the expression of FceR2/CD23
on normal human Mo is of particular interest in view of the role that this lym-
phokine may have in the regulation of the IgE system. IL-4 has been shown to
induce the in vitro synthesis of IgE by LPS-activated murine B cells (33). In
addition, IL-4 is involved in the in vivo control of IgE production; the injection
of anti-BSF-1 mAb to mice infected with Nippostrongylus brmiliensis has been
reported to block the IgE response (34). Finally, we have recently shown that
the supernatant of a Th2-like human alloreactive T cell clone, secreting IL-4 and
not IFN-y and IL-2 (35), can induce IgE synthesis by normal B cells, and that
this IgE enhancing ability is IL-4 dependent Qabara H. H., S . J. Ackerman, D.
Vercelli, T. Yokota, K. Arai, J. Abrams, A. M. Drorak, M. C. Lavigne, J. Banch-
ereau, J. de Vries, D.Y.M. Leung, and R. S. Geha, submitted for publication).
The same supernatant is also able to induce the expression of
FceR2/CD23 on Mo and B cells (Vercelli D., D. Y. M. Leung, H. H. Jabara, and
R. S. Geha, manuscript in preparation). It is therefore likely that IL-4 plays an
important, if not crucial, role in the modulation of the IgE system by upregu-
lating not only the synthesis of IgE, but also the expression of its receptors. An
increased secretion of IL-4 in allergic disease may be at least partially respon-
sible for the high percentage of circulating Mo bearing FceR2/CD23 observed
in these disorders. The simultaneous presence of a large population of FceR2/
CD23+ Mo and high concentrations of serum IgE may enhance receptor-ligand
interactions on the Mo membrane and promote the release of Mo-derived
mediators important for the inflammatory pathogenesis of allergic reactions.
Summary
rIL-4 (B cell stimulatory factor 1) induces the expression of FceR2/CD23 on
normal human monocytes (Mo). FceR2/CD23 induction was detectable both by
flow cytometry using anti-CD23 mAbs as well as soluble IgE, and by the immu-
noprecipitation with CD23-specific mAb or IgE of a 45-kD band from 1251-lac-
toperoxidase-labeled Mo. FceR2/CD23 was fully expressed after a 24-h incu-
bation with rIL-4, and was still detectable after 72 h from the addition of IL-4.
This effect was specific, because none of the other rILs tested (IL-1, IL-2, IL-
3, IL-5, B cell stimulatory factor 2, granulocyte-macrophage colony stimulating
factor, and IFN-y) could induce FceR2/CD23, either alone or in various com-
binations. No synergism was observed between IL-4 and other ILs. IFN-y was
not able to inhibit the IL-4-induced expression of FceR2/CD23 on Mo, neither
when added to the culture together with IL-4, nor when added 36 h earlier.
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